PDCD1 and metastatic melanoma: For example, the PD1.3 (rs11568821) polymorphism has been associated with better clinical outcomes in patients with metastatic melanoma undergoing anti-PD-1 therapy, indicating its utility in predicting therapeutic efficacy.